<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 24, 1996
Roberts Pharmaceutical Corporation
--------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 1-10432 22-2429994
- ----------------- ------------- --------------
(State or other (Commission (IRS Employer
jurisdiction File Number) Identification
of incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive office, including zip code)
Registrant's telephone number, including area code: (908)389-1182
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
<PAGE>
Item 5. Other Events.
-------------
On July 24, 1996, Roberts Pharmaceutical Corporation announced that
inventory is in place for the near-term Canadian launch of Advantage 24(R), a
vaginally delivered contraceptive gel.
Advantage 24 broadens the women's health-care, product line marketed by
Roberts Pharmaceutical Canada which includes Replens(R), a vaginal
moisturizer, Estrace(R), for estrogen replacement therapy, RIMSO-50(R), for
interstitial cystitis, GLAXAL(R) Base, a moisturizing cream, Prenavite(R), a
prenatal vitamin supplement, and Trandate(R) injection, which is often used to
treat hypertension in pregnant women.
Advantage 24, which Roberts will introduce into the over-the-counter
Canadian marketplace, employs a patented Bioadhesive Delivery System to disperse
nonoxynol-9, a widely used spermicide. Based on its favorable safety profile,
Advantage 24 is the only such product to be selected by the United Nations
Global Program on HIV/AIDS (UNAIDS)for major international study for the
prevention of the heterosexual transmission of sexually transmitted diseases
including the human immunodeficiency virus (HIV).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Roberts Pharmaceutical Corporation
----------------------------------
(Registrant)
By: /s/ Anthony A. Rascio
-------------------------------
Anthony A. Rascio
Vice President
Date: July 26, 1996
